New Injection Targets Belly Fat by Destroying Fat Cells, Early Trials Show

GLP-1 drugs like Ozempic and Wegovy help many people lose weight, but keeping it off after stopping the medication is hard. An experimental injection called CBL-514 takes a different approach. Instead of shrinking fat cells, it makes them die off on their own. In early human trials, it reduced both the fat under the skin and the visceral fat around organs, which is the type most closely linked to type 2 diabetes, heart attacks, and strokes. Animal studies also suggest it may reduce weight regain after GLP-1 treatment ends, though that has not been tested in people. Here is what the research shows so far, what it doesn’t, and what you can do now to protect your health.

How CBL-514 Destroys Fat Cells

Most weight loss approaches shrink the fat stored inside your fat cells. CBL-514, an experimental injection, works differently. It makes fat cells die off on their own through a natural process called apoptosis. The drug is designed to target adipocytes, the cells that store fat, and leave other cells alone.

CBL-514 was developed by Caliway Biopharmaceuticals in New Taipei City, Taiwan. Early results were presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy.

The drug acts on two types of belly fat, and they affect your health in different ways.

Subcutaneous fat is the soft layer right under your skin, the part you can pinch. Visceral fat sits deep inside your abdomen, around organs like the liver and intestines. It is active tissue that interferes with how your body controls blood sugar and metabolism. Too much of it raises the risk of insulin resistance, type 2 diabetes, heart attacks, and strokes.

This is why visceral fat matters so much. Liposuction and tummy tuck surgery mainly deal with fat under the skin. They don’t reach the fat around your organs.

So what does the evidence show so far? In phase 2 human trials, 69.6% of people who received CBL-514 lost at least 150 mL of subcutaneous fat by the eight-week follow-up. No one in the placebo group reached that amount. In animal studies, the drug lowered body weight and reduced both subcutaneous and visceral belly fat.

What the Trials Showed About Visceral Fat

To see how CBL-514 affects the fat around organs, Professor W. Timothy Garvey of the University of Alabama at Birmingham and Yu-Fang Ling of Caliway Biopharmaceuticals analyzed data from two phase 2 trials (CBL-0204 and CBL-0205). They looked only at participants who had MRI scans, which can measure fat deep inside the abdomen.

Adults with a BMI of 22 to 30 received injections in the lower abdomen every three weeks, for up to 12 weeks. Doses went up to 600 mg. People with more abdominal fat got more injections, and treatment stopped once their fat layer fell below a set thickness. Scans were taken before treatment, four weeks after the last injection, and again at 8 to 12 weeks after it.

Follow-up data were available for 40 people: 23 who received CBL-514 and 17 who received a placebo. Average visceral fat at the start was 563.85 mL in the treatment group and 659.81 mL in the placebo group.

Four weeks after the last injection:

• CBL-514 group: visceral fat dropped by an average of 12.01%
• Placebo group: visceral fat rose by an average of 5.68%

That is a 17.69 percentage point gap. The gap grew at the later check-up (eight weeks after the last dose in one trial, 12 weeks in the other):

• CBL-514 group: visceral fat was still 10.45% below the starting level
• Placebo group: visceral fat was 11.76% above the starting level

The difference between the groups was now 22.21 percentage points. This suggests the effect lasted for weeks after the injections ended.

The researchers concluded that CBL-514 significantly reduced visceral fat compared with placebo. These are small, early trials, so larger studies need to confirm the results.

Could It Help Prevent Weight Regain After GLP-1 Drugs?

GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound have changed obesity treatment. Many people lose a lot of weight on them. But keeping that weight off is hard, and many people regain weight after they stop the medication.

The researchers wanted to know if destroying fat cells could help with this problem. So they tested CBL-514 together with tirzepatide, a drug used for obesity and type 2 diabetes, in animals.

What they found in animals:

• Combining CBL-514 with tirzepatide led to more weight loss than tirzepatide alone.
• After tirzepatide was stopped, rats that had received both drugs regained less weight than rats that had received tirzepatide only.

The researchers’ explanation is a hypothesis, not a proven fact. Fewer fat cells means less room to store fat. If that is true, fat may build up more slowly once the GLP-1 drug is stopped.

Weight loss improves blood pressure, blood sugar, and cholesterol. When the weight comes back, those gains can be lost. Professor Garvey believes this approach could eventually help people keep these health improvements.

There is an important limit here. These findings come from animal studies only. No one has yet shown that CBL-514 prevents weight regain in people. That will need to be tested in future clinical trials.

Safety, Health Benefits, and What Comes Next

In the trials, CBL-514 was generally well tolerated. Most side effects were reactions at the injection site, such as pain, swelling, and redness. They were mild to moderate, and no serious adverse events were reported. With only 40 people in the visceral fat analysis, though, rarer problems could still show up in larger groups.

A smaller waistline is the most visible result, but it is not the main goal. Professor Garvey said patients will likely be pleased by the cosmetic effect, yet what matters for health is weight loss, less visceral fat, and better blood pressure and cholesterol. The trials measured fat volume, so those health improvements have not been confirmed yet.

Liposuction and tummy tuck surgery are more invasive and mainly target fat under the skin. CBL-514 is an injection that, in these early trials, reduced both subcutaneous and visceral fat. Professor Garvey called it “a highly innovative approach to obesity pharmacotherapy.”

CBL-514 is still experimental. Recruitment for the first of two phase 3 trials was underway at the time of the announcement. Both are randomized, placebo-controlled studies testing whether the drug can safely and effectively reduce abdominal fat without surgery. Initial results are expected at the end of 2027.

My Personal RX on Keeping Belly Fat Off for Good

Losing weight is only half the job. Keeping it off, and protecting your heart and metabolism along the way, is the other half. These habits help whether or not you take a GLP-1 drug.

These are the steps I give my own patients. Talk to your doctor before you change any medication or start a new supplement.

1. Measure Your Waist: The scale doesn’t show where your fat sits. Once a month, measure around your waist at the belly button and share the number with your doctor.
2. Plan Before You Stop Medication: If you take a GLP-1 drug, ask your doctor how to taper and which habits to build first.
3. Lift Weights Twice a Week: Strength training helps you keep muscle while you lose fat.
4. Eat Protein at Every Meal: Protein keeps you full and protects muscle. My Weight Loss Bundle combines Protein Plus, MetaBurn, and Magnesium Essentials to help control cravings, keep energy steady, and preserve lean muscle.
5. Walk After Meals: Even 10 minutes helps your body manage blood sugar.
6. Protect Your Sleep: Aim for seven to nine hours. Poor sleep increases hunger and cravings.
7. Manage Stress: Stress often drives emotional eating. MindBiotic chewables combine probiotics, prebiotics, and Ashwagandha KSM-66 to support your gut-brain axis, stress response, and mood.
8. Support Digestion: If you often feel bloated or have indigestion, Digestive Enzymes can help with relief and nutrient absorption.
9. Check Your Numbers: Visceral fat affects blood pressure, blood sugar, and cholesterol. Get them tested at least once a year.
10. Learn the Gut-Brain Link: My book, Heal Your Gut, Save Your Brain, explains how gut health shapes your appetite, mood, and long-term weight.

Sources:

1. New injection makes fat cells self-destruct. (2026). ScienceDaily. https://www.sciencedaily.com/releases/2026/10/261008102713.htm